U.S. Veterinary Anti-infectives Market (2025 - 2033)

U.S. Veterinary Anti-infectives Market Summary

The U.S. veterinary anti-infectives market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 3.55 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, increasing R&D initiatives, a boost to prudent antibiotic use, development of novel treatments, and growing applications of Artificial Intelligence (AI).

The veterinary anti-infectives market in the U.S. is undergoing a significant transformation, driven by rising concerns over antimicrobial resistance (AMR) in companion animals and livestock. A January 2025 study highlighted in News-Medical underscores how household dogs can harbor and transmit antibiotic-resistant Salmonella, elevating the risk of zoonotic infections. This has raised awareness among veterinarians and pet owners, leading to a growing demand for more targeted and safer anti-infective solutions in the companion animal segment. Veterinary practices are increasingly cautious about the indiscriminate use of broad-spectrum antibiotics, prompting interest in narrow-spectrum drugs, resistance-mitigating therapies, and even preventive care options like probiotics. This trend also fuels the growth of veterinary diagnostics, especially for susceptibility testing that helps guide treatment decisions responsibly.

Innovations to reduce antibiotic reliance further shape the market in the livestock sector. A Penn State study from December 2024 revealed a promising new treatment for mastitis in dairy cows using bacteriophages instead of antibiotics. This breakthrough highlights the expanding market for antibiotic alternatives, including phage therapies, immunomodulators, peptides, and other biologics. Regulatory pressure from the FDA and USDA to curb routine antibiotic use in food-producing animals has increased the adoption of such alternatives, especially among dairy and beef producers. These stakeholders are now seeking effective treatments that comply with antimicrobial stewardship guidelines while maintaining herd health and productivity, thus broadening the veterinary anti-infectives landscape beyond conventional antibiotics.

Meanwhile, the American Veterinary Medical Association (AVMA) has emphasized the importance of communication between veterinarians and animal owners around responsible antibiotic use. This stewardship-led approach is reshaping prescribing behavior across U.S. veterinary practices. As veterinarians prioritize diagnosis-driven treatments and reduce empirical antibiotic use, there is an increasing demand for diagnostics, sensitivity testing, and more refined anti-infective therapies. Pharmaceutical companies are responding by developing precision drugs and educational resources that align with stewardship principles. This shift ensures better health outcomes and drives sustained market demand for innovation in veterinary anti-infectives.

In summary, the U.S. market is propelled by three major forces: the detection of AMR threats in pets, the emergence of non-antibiotic treatments for livestock diseases, and a growing culture of veterinary stewardship. These factors drive market players to diversify product portfolios, invest in R&D for safer alternatives, and develop tools supporting responsible antibiotic use. The result is a market rapidly evolving toward precision, sustainability, and innovation in the fight against antimicrobial resistance.

Tackling antibiotic resistance: U.S. vs Europe Analysis

Market Concentration & Characteristics

The U.S. veterinary anti-infectives industry is marked by high innovation, with companies continuously introducing targeted, user-friendly solutions to combat rising infectious diseases. A recent example is the April 2025 launch of a smaller 5 mL Vetlen pouch, designed for precise antibiotic dosing and reduced waste in small animals. Such innovations support both clinical effectiveness and responsible antibiotic use.

The market exhibits a moderate level of M&A activity, with companies strategically acquiring specialized platforms to expand market presence and streamline distribution. For instance, in January 2025, Revelation Pharma’s acquisition of Cascade Specialty Pharmacy enhanced its reach in the ENT and animal health sectors. Such moves strengthen supply chains and broaden access to compounded and specialty anti-infective therapies.

Regulations significantly impact the U.S. market, shaping product approvals, usage, and supply dynamics. Ongoing efforts by agencies like the FDA aim to curb antimicrobial resistance through stricter oversight and stewardship guidelines. In addition, proposed tariffs on veterinary medicines, as highlighted by the Georgia Veterinary Medical Association (GVMA), could further affect market access and pricing. Such regulatory developments influence both the availability and responsible use of anti-infective products.

While the veterinary anti-infectives market in the U.S. is dominated by key players like Zoetis, Merck, Boehringer Ingelheim, and Dechra, it is seeing rising adoption of regional and cost-effective substitutes. Growing concerns over antibiotic resistance and regulatory shifts have fueled interest in alternative therapies such as plant-based products, probiotics, etc. Startups increasingly focus on developing targeted, resistance-bypassing treatments, contributing to a diverse and evolving substitute landscape. These alternatives offer cost benefits and align with antimicrobial stewardship goals.

The industry is undergoing moderate regional expansion, with manufacturers aiming to grow their international footprint through strategic product launches. For example, Jaguar Health is pursuing EU approval for Canalevia to treat general diarrhea in dogs, signaling efforts to tap into global markets. Such expansion allows U.S.-based companies to boost revenues, diversify regulatory risk, and introduce novel therapies to a broader veterinary audience.

Animal Insights

The livestock segment accounted for the largest revenue share, 60.44%, in 2024. This is driven by the high disease burden among livestock such as cattle, swine, poultry, and sheep, necessitating frequent preventive and therapeutic use of anti-infectives. The growing demand for animal protein, especially beef, pork, and poultry, reinforces the need for robust disease management. According to the USDA 2024 Livestock Report, U.S. poultry production reached over 52 billion pounds in 2023, while beef and veal production exceeded 26 billion pounds. Increased emphasis on food safety standards, sustainable animal farming, and compliance with veterinary feed directive (VFD) regulations has led to the adoption of more targeted and regulated anti-infective therapies. Additionally, livestock producers increasingly invest in anti-infectives to maintain herd health, minimize economic losses, and meet domestic and international meat export standards.

The companion animal segment is projected to grow at the fastest CAGR over the forecast period. As of 2024, nearly 66% of U.S. households own a pet, with dogs and cats being the most common, according to the American Pet Products Association. This surge in pet ownership is accompanied by increased awareness of pets' health and emotional benefits, such as reduced stress and improved mental well-being. Owners are increasingly investing in preventive veterinary care, including routine vaccinations and infection control, leading to higher demand for targeted anti-infective therapies tailored for companion animals. The market also benefits from a growing range of specialized, easy-to-administer formulations and increased veterinary access. Emotional bonding, rising disposable income, and pet humanization trends are key drivers of advanced therapeutic spending in this segment, positioning it as a high-growth area within the U.S. veterinary landscape.

Product Insights

The antimicrobials segment dominated the market with a revenue share of around 52.38% in 2024, driven by the high burden of bacterial infections in livestock and companion animals. Commonly used classes like tetracyclines and penicillins remain essential for treating respiratory and gastrointestinal diseases. Regulatory actions, such as the FDA's Veterinary Feed Directive and GFI #263, have restricted non-therapeutic antibiotic use, ensuring greater veterinary oversight. National initiatives like the CDC's AMR Challenge support antimicrobial stewardship and innovation. These efforts sustain demand while addressing growing concerns around food safety and antibiotic resistance.

The antiviral segment in veterinary anti-infectives is poised for the fastest growth over the forecast period due to rising cases of viral diseases like BRSV in cattle, PRRSV in swine, and canine parvovirus. These infections cause significant economic losses and increase demand for targeted antivirals. Federal programs by USDA-APHIS and NAHLN are enhancing viral surveillance and outbreak response. Advances in antiviral R&D-including mRNA and nanoparticle-based therapies-are accelerating innovation. One health initiative by the CDC and USDA further supports cross-sector investment, reinforcing the segment's rapid expansion.

Route of Administration Insights

The oral segment dominated the market with a 72.60% share in 2024, driven by its ease of administration across companion animals and food-producing livestock. Oral dosage forms-such as chewables for dogs and medicated feed additives for cattle or swine-enable mass medication without requiring veterinary supervision, improving compliance and lowering treatment costs. The FDA's veterinary feed directive (VFD) supports the regulated use of oral antimicrobials like tetracyclines and macrolides in feed for disease control.

The "Others" segment, encompassing topical, rectal, and intrauterine routes, is projected to grow at the fastest CAGR from 2025 to 2033 in the veterinary anti-infectives market. This is fueled by the growing adoption of localized therapies for reproductive, dermatological, and species-specific infections, especially in dairy and equine care. For example, intrauterine antibiotics are frequently used for treating bovine endometritis, while topical antimicrobials are preferred for skin infections in companion animals. The increasing shift toward precision treatment aligns with USDA-supported stewardship programs that promote targeted drug use.

Type Insights

By type, the OTC or over-the-counter segment dominated the market in 2024 as pet and livestock owners increasingly turned to affordable, accessible, and convenient products for managing minor health issues. OTC products like dewormers, topical antiseptics, and basic antimicrobials remain widely available through retail outlets and online platforms such as Chewy and Tractor Supply Co. This trend reflects a preference for self-managed care for non-critical conditions, especially in rural and backyard animal settings.

The prescription segment is estimated to grow at the fastest CAGR over the forecast period primarily due to tightening U.S. regulatory oversight. The FDA's Guidance for Industry (GFI) implementation in 2023 reclassified all medically essential antimicrobials from OTC to prescription-only status, requiring veterinary oversight for their use in food animals. This shift drives increased reliance on veterinarians for diagnosis and treatment, particularly for systemic infections and herd-level disease control.

Distribution Channel

The retail pharmacies segment dominated the market in terms of share in 2024. This is driven by their accessibility, regulatory compliance, and consumer trust. National chains like CVS and Walmart offer a broad range of veterinary medications and vaccines supported by well-developed distribution systems. The growing integration of digital health platforms-such as automated refills and e-prescriptions-has further improved service accuracy and convenience, minimizing prescription errors.

The e-commerce segment is estimated to grow at the fastest CAGR over the forecast period, fueled by 24/7 availability, doorstep delivery, and competitive pricing. Platforms like Chewy, PetMeds, and Amazon Veterinary Pharmacy offer extensive catalogs of prescription and OTC anti-infectives for companion animals and livestock. The pandemic accelerated the shift toward online purchasing, and with rising internet penetration and digital literacy among U.S. consumers, e-commerce is becoming a preferred channel for veterinary medication access.

Key U.S. Veterinary Anti-infectives Company Insights

The U.S. veterinary anti-infectives industry is shaped by strict regulatory oversight, particularly FDA-led efforts to combat antimicrobial resistance and potential pricing shifts due to proposed tariffs. While major players like Zoetis and Merck dominate, there is rising interest in alternative therapies, such as probiotics and plant-based solutions, driven by stewardship goals. Innovation remains strong, with new dosage formats and targeted therapies improving compliance and reducing waste. Moderate M&A activity, such as Revelation Pharma's 2025 acquisition of Cascade, supports supply chain expansion. In addition, global market outreach by U.S. firms like Jaguar Health signals increasing regional diversification.

Recent Developments

• In February 2025, Elanco launched Pradalex, a novel injectable antibiotic for treating bovine and swine respiratory diseases, marking the first new FDA‑approved molecule for BRD and SRD in approximately 20 years. This single-dose, low-volume solution offers rapid bacterial elimination, extended pathogen coverage, and a favorable withdrawal profile, expanding therapeutic options for U.S. livestock producers

• In January 2025, Veterinary Pharmaceutical Solutions introduced UltrAmox, a new patent‑pending, water-soluble amoxicillin formulation tailored for swine and poultry, which retains over 90% potency after 24 hours when properly mixed; this enhanced stability may allow producers to use less antibiotic over the animals' lifespan, supporting optimized dosing and improved antibiotic stewardship

• In January 2025, Revelation Pharma launched Revelation Animal Health, establishing a nationwide platform focused on animal health compounding. This new division aims to provide tailored, high-quality compounded medications for companion and large animals, strengthening access to specialized veterinary therapies across the U.S. The move positions Revelation as a leader in customized veterinary pharmaceutical solutions.

U.S. Veterinary Anti-infectives Market